Trisalus Life Sciences, Inc. — Form 8-K Summary
Reporting date: October 2, 2023. The filing reports a material financing agreement, an unregistered equity issuance framework, and a warrant repurchase program. It does not provide a quarterly or annual financial results update.
Business Context and Reporting Period
TriSalus Life Sciences entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., a fund managed by Yorkville Advisors Global, LP. The commitment period begins October 2, 2023 and ends on the first day of the month following the 24-month anniversary of that date.
Key Financial and Capital Markets Terms
- TriSalus may, but is not obligated to, sell up to $30 million of common stock to Yorkville during the commitment period.
- Advance amounts are generally limited to the greater of 100% of the average daily trading volume during the preceding 10 trading days or 1 million shares.
- Pricing may be based on either 96% of VWAP for the applicable same-day pricing period or 97% of the lowest VWAP over a three-trading-day pricing period.
- Yorkville is subject to a 4.99% beneficial ownership limitation and generally a 19.99% exchange cap, subject to specified exceptions, including stockholder approval or satisfaction of Nasdaq minimum-price rules.
- Issuances may be reduced if trading volume during the pricing period falls below the specified volume threshold.
- The company paid a $25,000 structuring fee to YA Global II SPV, LLC and a $300,000 commitment fee to Yorkville.
- The company must register the shares issuable under the agreement for resale, and the registration statement must be declared effective before any shares may be sold under the agreement.
- The filing does not provide revenue, profit, cash flow, margin, debt, cash balance, liquidity runway, or other operating performance metrics.
Material Changes and Unusual Items
- The equity purchase agreement provides a potential source of financing but does not require TriSalus to draw funds or issue shares.
- Shares would be issued at a discount to market-based prices, creating potential dilution to existing stockholders if advances are made.
- The board approved a program to repurchase some or all publicly held warrants, with authorized aggregate expenditures of up to $4 million.
- Warrant repurchases may occur in open-market or privately negotiated transactions. The company may use Rule 10b5-1 purchase plans.
- The warrant repurchase program does not obligate the company to purchase warrants and may be terminated, increased, or decreased by the board at its discretion.
- The equity sales are expected to rely on the Securities Act Section 4(a)(2) exemption based on Yorkville’s representation that it is an institutional accredited investor.
Outlook, Risks, and Contingencies
Management did not provide operating or financial guidance in this filing. Potential proceeds, share issuances, and warrant repurchases remain uncertain. Access to the Yorkville facility is contingent on the effective filing of a resale registration statement and is subject to ownership, exchange-cap, trading-volume, and Nasdaq-related limitations.
Key risks include dilution from discounted equity issuances, dependence on market trading volume and share price, the company’s ability to register shares, potential use of cash for warrant repurchases, and the possibility that the financing facility will not produce the anticipated proceeds. The company incorporated by reference the risk factors in its August 16, 2023 Form 8-K and future SEC filings.
Important Facts for Investors to Verify
- Whether and when TriSalus submits advance notices and actually issues shares to Yorkville.
- The effectiveness and scope of the resale registration statement.
- The number of shares issued, the applicable discount, and resulting dilution.
- Cash proceeds received after fees and any related financing costs.
- Whether the 19.99% exchange cap or Nasdaq stockholder-approval requirements affect future advances.
- The number and price of warrants repurchased, total program expenditures, and the effect on cash and outstanding warrants.
- Updated liquidity, operating results, debt, and cash-flow information in subsequent periodic filings.